The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.
The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and educational programme of the Congress. The industry has no influence on the content of the programme or speaker selection. All ESMO Colloquia are open to multi-sponsor support and interested sponsors can contact ESMO for more information on future programmes at colloquia@esmo.org.
View the complete ESMO Congress 2023 programme online
Optimising outcomes for patients with advanced renal cancer
Saturday, 21 October 2023
18:30-20:00 CEST (Central European Summer Time)
Congress Hall 3 – Salamanca Auditorium
This educational activity is provided by ESMO and supported by an unrestricted educational grant from Eisai.
View the ESMO colloquium details
Learning Objectives
- To provide an update on the efficacy of new combination regimens including VEGFR TKIs and immune checkpoint inhibitors in patients with advanced renal cancer.
- To inform on clinical and molecular prognosticators and decision-making algorithms in order to assist the oncologist in optimal therapeutic choices for RCC patients.
- To provide insights in ongoing research for novel, escalated and de-escalated therapeutic regimens.
The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
Sunday, 22 October 2023
13:00-14:30 CEST (Central European Summer Time)
Congress Hall 3 – Toledo Auditorium
This educational activity is provided by ESMO and supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca.
View the ESMO colloquium details
Learning Objectives
- To provide information about the positioning of ADCs in the emerging treatment landscape for patients with advanced, inoperable non-small-cell lung cancer.
- To educate health care professionals on the optimal clinical algorithms for the timely detection and efficient management of toxicities of ADCs.
- To share insights into ongoing research for the identification of biomarkers for novel combinations of ADCs with targeted compounds in thoracic oncology.
Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
Sunday, 22 October 2023
18:30-20:00 CEST (Central European Summer Time)
Congress Hall 7 – Oviedo Auditorium
This educational activity is provided by ESMO and supported by Eli Lilly and Company.
View the ESMO colloquium details
Learning Objectives
- To inform on advances in state of the art care for patients with NSCLC driven by rare molecular aberrations.
- To provide insights on availability of molecular testing of solid tumours in Europe and its impact on precision medicine.
- To update the user’s knowledge on next generation sequencing technologies in oncology.